Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KURA – Kura Oncology, Inc.

Float Short %

10.36

Margin Of Safety %

-35

Put/Call OI Ratio

0.15

EPS Next Q Diff

-0.03

EPS Last/This Y

-0.32

EPS This/Next Y

0.09

Price

11.64

Target Price

33

Analyst Recom

1.33

Performance Q

45.32

Relative Volume

0.73

Beta

0.23

Ticker: KURA




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10KURA10.330.130.0328729
2025-11-11KURA10.70.120.0131106
2025-11-12KURA10.660.110.0932427
2025-11-13KURA10.650.120.7532428
2025-11-14KURA11.20.160.1033872
2025-11-17KURA10.830.170.8234277
2025-11-18KURA11.080.210.1135014
2025-11-19KURA11.340.220.0734677
2025-11-20KURA10.970.220.3734774
2025-11-21KURA11.160.220.2734688
2025-11-24KURA11.730.100.4425828
2025-11-25KURA11.590.110.1126263
2025-11-26KURA11.980.110.1826299
2025-12-01KURA11.440.110.0626202
2025-12-02KURA11.130.112.4726214
2025-12-03KURA11.960.160.0827322
2025-12-04KURA11.980.150.0928366
2025-12-05KURA11.960.150.0029985
2025-12-08KURA11.650.150.3129788
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10KURA10.32147.7-150.2-2.15
2025-11-11KURA10.69147.7-147.9-2.28
2025-11-12KURA10.67147.7-115.9-2.28
2025-11-13KURA10.68147.7-111.7-2.28
2025-11-14KURA11.2075.3-156.5-2.28
2025-11-17KURA10.8375.3-94.5-2.28
2025-11-18KURA11.0975.3-138.0-2.33
2025-11-19KURA11.3275.3-138.0-2.33
2025-11-20KURA10.9575.3-97.9-2.31
2025-11-21KURA11.1672.3-133.5-2.31
2025-11-24KURA11.7472.3-158.4-2.31
2025-11-25KURA11.6072.3-113.4-2.34
2025-11-26KURA11.9872.3-144.4-2.34
2025-12-01KURA11.4250.5-81.5-2.34
2025-12-02KURA11.1350.5-101.8-2.34
2025-12-03KURA11.9750.5-175.2-2.34
2025-12-04KURA11.9950.5-122.2-2.34
2025-12-05KURA11.9550.5-119.6-2.34
2025-12-08KURA11.6450.5- -2.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10KURA0.623.0412.64
2025-11-11KURA0.623.0412.64
2025-11-12KURA0.623.0410.33
2025-11-13KURA0.623.0410.33
2025-11-14KURA0.623.0410.33
2025-11-17KURA-0.849.4610.41
2025-11-18KURA-0.709.4610.41
2025-11-19KURA-0.709.4610.41
2025-11-20KURA-0.629.4610.41
2025-11-21KURA-0.629.4610.41
2025-11-24KURA-0.623.2410.29
2025-11-25KURA-0.843.2410.29
2025-11-26KURA-0.843.2410.37
2025-12-01KURA-0.843.3510.37
2025-12-02KURA-0.843.3510.37
2025-12-03KURA-0.843.3510.37
2025-12-04KURA-0.843.3510.37
2025-12-05KURA-0.843.3510.36
2025-12-08KURA-0.852.9810.36
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.85

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

-0.85

Institutional Transactions

2.98

Beta

0.23

Average Sales Estimate Current Quarter

81

Average Sales Estimate Next Quarter

89

Fair Value

7.59

Quality Score

23

Growth Score

24

Sentiment Score

21

Actual DrawDown %

72.9

Max Drawdown 5-Year %

-86.7

Target Price

33

P/E

Forward P/E

PEG

P/S

9.74

P/B

4.18

P/Free Cash Flow

12.19

EPS

-2.48

Average EPS Est. Cur. Y​

-2.34

EPS Next Y. (Est.)

-2.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-208.48

Relative Volume

0.73

Return on Equity vs Sector %

-116.3

Return on Equity vs Industry %

-101.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

Kura Oncology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today
news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance
stock history KURA – Kura Oncology, Inc. invest stock market
stock prices KURA premarket after hours
ticker KURA fair value insiders trading